Intra-Cellular Therapies v. Zydus Cadila: CAPLYTA® Lumateperone Patent Consolidation
Intra-Cellular Therapies filed a patent infringement action in New Jersey against Zydus Cadila and Zydus Lifesciences, asserting three patents protecting CAPLYTA® (lumateperone) capsules across three dosage strengths. The case was consolidated for pretrial purposes within 70 days of filing, signalling coordinated multi-case Hatch-Waxman litigation strategy.
Three-Patent Hatch-Waxman Battle Over Generic CAPLYTA® Entry
On November 1, 2024, Intra-Cellular Therapies, Inc. filed suit in the U.S. District Court for the District of New Jersey against Zydus Cadila and its parent Zydus Lifesciences Ltd., asserting infringement of three patents — US12128043B2, US12122792B2, and US12090155B2 — covering lumateperone, the active ingredient in CAPLYTA®, a branded antipsychotic approved in capsule strengths of 10.5 mg, 21 mg, and 42 mg. The defendants are seeking FDA approval for generic versions of those same dosage forms under the Hatch-Waxman Act.
Within 70 days of filing, on January 10, 2025, the court entered a stipulation and order consolidating this matter with related cases for pretrial purposes. Consolidation does not resolve the underlying infringement claims; rather, it streamlines discovery, claim construction, and pretrial proceedings across what is likely a broader wave of ANDA filer litigation over the lumateperone franchise. The substantive merits — whether Zydus’s ANDA product infringes the asserted claims — remain pending.
The speed of consolidation, at just 70 days, suggests the parties and the court moved efficiently to coordinate what is consistent with a multi-defendant Hatch-Waxman patent litigation. The public record does not disclose how many parallel cases were consolidated, the specific claim scope at issue, or whether any 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii) is in effect. What remains unknown is the relative strength of the asserted claims and whether any inter partes review challenges have been or will be filed against the three patents.
Filing to Case Consolidated in 70 days
70 days from filing to consolidation order — rapid procedural resolution typical of ANDA litigation coordination
Cases consolidated for pretrial: what this procedural step means
Consolidation is procedural, not a merits ruling
A consolidation order under Fed. R. Civ. P. 42(a) joins related cases for joint management of pretrial proceedings — discovery, scheduling, and claim construction — without resolving infringement or validity. The three asserted patents remain in dispute. Closing this docket entry reflects administrative consolidation, not a substantive outcome for either party.
No merits adjudicationConsolidation typically favours the patent holder in ANDA cases
For Intra-Cellular Therapies, consolidation concentrates all ANDA challengers into a single pretrial track, reducing litigation costs and preventing inconsistent rulings across multiple dockets. It also preserves the potential 30-month stay blocking generic market entry while the dispute is resolved — a significant commercial benefit protecting the CAPLYTA® franchise.
30-month stay likely in forceZydus faces coordinated multi-patent claim construction
Consolidation means Zydus Cadila and Zydus Lifesciences must contest three patents simultaneously in a unified proceeding alongside any other ANDA filers. While this can share discovery costs, it also subjects the challenger to claim construction rulings that bind all consolidated defendants, limiting tactical flexibility. Generic market entry remains blocked absent a court ruling or settlement.
Generic entry still blockedCAPLYTA® market exclusivity remains intact during litigation
Lumateperone generated substantial branded revenue for Intra-Cellular Therapies. Consolidation of ANDA litigation signals a coordinated enforcement strategy likely to extend market exclusivity through the litigation timeline. For formulary managers and competitors, the consolidated docket suggests generic lumateperone entry is not imminent, and the patent estate covering the product appears actively defended across multiple dosage strengths.
Exclusivity period extendedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Intra-cellular Therapies, Inc. | Company | Biopharmaceutical company — holder of US12128043B2, US12122792B2, and US12090155B2 covering lumateperone (CAPLYTA®)Search in Eureka ↗ |
| Defendant | Zydus Cadila | Individual | Generic pharmaceutical manufacturer and its parent seeking FDA approval for generic lumateperone capsules (ANDA filer)Search in Eureka ↗ |
| Co-Defendant | Zydus Lifesciences Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Katelyn O’Reilly | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Lauren Ruth Malakoff | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’Reilly Falanga LLP | Law Firm | Representing Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation and order consolidating cases for pretrial purposes is a procedural instrument, not a verdict on the merits. It reflects agreement between the parties — and court approval — to manage related Hatch-Waxman infringement actions jointly. No finding of infringement, validity, or enforceability has been made. The three asserted lumateperone patents remain live, and the substantive dispute over whether Zydus’s ANDA product infringes US12128043B2, US12122792B2, and US12090155B2 continues in the consolidated proceeding.
US12128043B2, US12122792B2 & US12090155B2 — lumateperone formulation patents
The three asserted patents — US12128043B2, US12122792B2, and US12090155B2 — protect lumateperone, a novel antipsychotic and antidepressant agent marketed as CAPLYTA®. All three carry 2024 application numbers (US18/602981, US18/240951, US18/494754), indicating recent grant as part of Intra-Cellular Therapies’ ongoing prosecution strategy. Lumateperone acts on serotonin, dopamine, and glutamate receptors with a differentiated mechanism claimed to reduce side-effect burden versus older antipsychotics. The patents cover formulation, dosage, and likely method-of-treatment claims across the approved capsule strengths.
For the CNS pharmaceutical sector, these patents represent a strategic portfolio defending CAPLYTA®’s commercial position in the schizophrenia and bipolar depression markets. Late-stage prosecution resulting in 2024-granted patents extending coverage over an already-approved product is a recognised lifecycle management technique. Any generic manufacturer targeting lumateperone must design around or invalidate all three patents — a significantly higher barrier than a single-patent block. Competitors developing PDE1 inhibitors or dopamine-serotonin modulators should monitor the claim scope closely.
Should your team run an FTO against US12128043B2, US12122792B2 & US12090155B2?
Any company developing, manufacturing, or seeking ANDA approval for lumateperone capsules — or structurally related antipsychotic formulations — should treat these three patents as active blocking rights. All three were recently granted and are being actively asserted in consolidated Hatch-Waxman litigation. Even novel CNS compounds with partial structural or mechanistic overlap with lumateperone may face infringement risk under method-of-treatment claims. A formal FTO analysis is essential before committing to IND or ANDA filing for any lumateperone-adjacent product.
PatSnap Eureka’s FTO Search Agent enables rapid claim mapping across all three asserted patents simultaneously, identifying prior art gaps, claim scope boundaries, and design-around opportunities. For ANDA filers already in litigation, Eureka’s consolidated patent landscape view can surface invalidity arguments across related prosecution history — critical intelligence before claim construction briefing closes in the D.N.J. consolidated proceeding.
Run a freedom-to-operate analysis on US12128043B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA patent cases in New Jersey: lumateperone & CNS drugs
Explore related Hatch-Waxman infringement cases in the District of New Jersey involving CNS drug formulation patents and multi-patent ANDA consolidation proceedings.
What this case signals for the branded antipsychotic IP landscape
Multi-patent ANDA consolidation in New Jersey is a textbook exclusivity defence. Here is what IP teams should watch.
Three overlapping patents create a layered exclusivity defence for CAPLYTA®
Asserting three separate patents — US12128043B2, US12122792B2, and US12090155B2 — across the same lumateperone product is a deliberate patent thicket strategy. Even if one patent is invalidated or not infringed, the others may independently block generic entry. R&D and IP teams in CNS pharma should map similar multi-patent coverage strategies for their lead assets.
New Jersey ANDA litigation consolidation is fast-tracked — expect tight discovery schedules
The 70-day path to a consolidation order in D.N.J. reflects the court’s experience with high-volume Hatch-Waxman dockets. Patent counsel defending or asserting ANDA cases here should prepare for compressed timelines on claim construction and expert discovery. Early landscape analysis of the asserted patent claims is essential before the consolidated schedule is set.
Intra-cellular v Zydus — key questions answered
Consolidation under Fed. R. Civ. P. 42(a) means related cases are managed jointly for pretrial purposes including discovery and claim construction. It does not resolve infringement or validity. In this case, the three asserted lumateperone patents — US12128043B2, US12122792B2, and US12090155B2 — remain in active dispute. The substantive question of whether Zydus’s ANDA product infringes those patents is still pending in the consolidated proceeding.
Intra-Cellular Therapies asserted three patents: US12128043B2 (application US18/602981), US12122792B2 (application US18/240951), and US12090155B2 (application US18/494754). All three were recently granted and cover lumateperone formulations and/or methods of treatment corresponding to CAPLYTA® capsules at 10.5 mg, 21 mg, and 42 mg dosage strengths.
The public record for case 3:24-cv-10240 does not expressly confirm a 30-month stay, but Hatch-Waxman litigation triggered by a paragraph IV ANDA certification typically activates an automatic 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii) if suit is filed within 45 days of notice. Given the filing timeline and the active consolidated litigation, generic lumateperone entry by Zydus appears to remain blocked pending resolution, though this is subject to the specific ANDA certification type and FDA filing details not disclosed in the public docket.
Under 35 U.S.C. § 315(b), an IPR petition must be filed within one year of service of a complaint alleging infringement. The complaint was filed November 1, 2024, meaning the IPR window likely closes around November 2025. All three patents — US12128043B2, US12122792B2, and US12090155B2 — are recently granted, and prior art availability depends on the claim scope established during prosecution. Zydus or any third party should conduct a prior art assessment promptly.
The District of New Jersey is the principal venue for Hatch-Waxman ANDA patent litigation in the United States due to the concentration of pharmaceutical companies and established judicial expertise with the Hatch-Waxman framework. Filing in D.N.J. also allows Intra-Cellular Therapies to consolidate multiple ANDA filer cases on a single docket, as occurred here within 70 days of filing, streamlining enforcement of the three lumateperone patents across all generic challengers.
PatSnap Eureka searches patents and litigation data to answer instantly.